Projects funded by the NCN
Genetically modified dendritic cells as a component of combined therapy immunomodulating the tumor microenvironment
2017/27/B/NZ6/02702
Keywords:
chemoimmunotherapy dendritic cells cytokines
Descriptors:
- NZ6_3: Animal immunology
- NZ5_8: Animal disease treatment
- NZ6_5: Virology
Panel:
NZ6 - Human and animal immunology and infection: immunity, immune disorders, immunotherapy, infectious and invasive diseases, microbiology, transplantology, allergology
Host institution :
Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk
woj. dolnośląskie
Principal investigator (from the host institution):
dr hab. Elżbieta Pajtasz-Piasecka
Number of co-investigators in the project: 6
Call: OPUS 14 - announced on 2017-09-15
Amount awarded: 1 153 200 PLN
Project start date (Y-m-d): 2018-07-31
Project end date (Y-m-d): 2022-07-30
Project duration:: 48 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Equipment purchased [PL]
- Zbiornik na ciekły azot do przechowywania materiału biologicznego wraz z wyposażeniem (70 000 PLN)
- COMPRO Ms Office.
- Corel.
- GraphPad.
- Sartorius Waga SECURA.
- ACEA NovoExpress.
- MORELE Monitor.
- Oprogramowanie do opracowania wyników (2 400 PLN)
- komputer, nagrywarka DVD.
Information in the final report
- Publication in academic press/journals (4)
- Immunomodulatory potential of anticancer therapy composed of methotrexate nanoconjugate and dendritic cell‑based vaccines in murine colon carcinoma.Authors:A. Szczygieł, N. Anger‑Góra, K. Węgierek‑Ciura, J. Mierzejewska, J. Rossowska, T. Goszczyński, M. Świtalska, E. Pajtasz‑PiaseckaAcademic press:Oncoogy Reports (rok: 2021, tom: 45, strony: 945-962), Wydawca: Spandidos PublicationsStatus:PublishedDOI:10.3892/or.2021.7930 - link to the publication
- Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccinesAuthors:Katarzyna We˛ gierek-Ciura*, Jagoda Mierzejewska, Agnieszka Szczygieł, Joanna Rossowska, Anna Wro´ blewska, Marta S´ witalska, Tomasz M. Goszczyn´ ski, Boz˙ena Szermer-Olearnik and Elz˙ bieta Pajtasz-PiaseckaAcademic press:Frontiers in Immunology (rok: 2023, tom: 14, strony: 1212606), Wydawca: FrontiersStatus:PublishedDOI:10.3389/fimmu.2023.1212606 - link to the publication
- Perspektywy zastosowania interleukiny 15 w terapii przeciwnowotworoweAuthors:Katarzyna Węgierek, Elżbieta Pajtasz-PiaseckaAcademic press:Postepy Hig Med Dosw (online), 2019; 73: 850–864 (rok: 2019, tom: 73, strony: 850–864), Wydawca: Index CopernicusStatus:PublishedDOI:10.5604/01.3001.0013.7194 - link to the publication
- The modulation of local and systemic anti-tumor immune response induced by methotrexate nanoconjugate in murine MC38 colon carcinoma and B16 F0 melanoma tumor models" has been reviewedAuthors:Agnieszka Szczygieł, Katarzyna Węgierek-Ciura, Jagoda Mierzejewska, Anna Wróblewska, Joanna Rossowska, Natalia Anger-Góra, Bożena Szermer-Olearnik, Marta Świtalska, Tomasz M. Goszczyński, Elżbieta Pajtasz-PiaseckaAcademic press:American Journal of Cancer Research (rok: 2023, tom: 13(10), strony: -4623-4643), Wydawca: e-Century Publishing CorporationStatus:PublishedDOI: